Business Context and Reporting Period
This Form 8-K Current Report, dated June 10, 2003, is filed by AI Software, Inc. (the "Company"), a Nevada corporation. The report details a strategic pivot from artificial intelligence software development to the biotechnology sector. On June 10, 2003, the Company acquired 100% of the issued and outstanding shares of Pluristem Ltd. ("Pluristem"), an Israeli research and development company, making it a wholly-owned subsidiary. This acquisition was undertaken to develop and commercialize stem cell expansion technology, specifically the PluriX™ Bioreactor system, following the Company's inability to successfully implement its original software business plan.
Key Financial Metrics
The filing does not provide historical revenue, profit, cash flow, or margin data for the Company or the acquired subsidiary. The transaction consideration and immediate financial obligations are as follows:
- Acquisition Consideration: The Company paid US$1,000 in cash to Abramovich Trust Company Ltd. for the shares of Pluristem.
- Line of Credit: The Company provided Pluristem with a line of credit in the amount of US$500,000.
- Projected Expenses (Next Fiscal Year):
- Management Compensation: $306,000
- Research and Development: $1,045,000
- Legal Expenses: $227,000
- Business Development and Travel: $180,000
- Capital Expenditures (R&D Facilities): $167,000
- Revenue Outlook: The Company expects no revenues from operations for the next three years.
Material Changes
The primary material change is the complete shift in business focus and the acquisition of a new subsidiary:
- Business Pivot: The Company abandoned its "Randomix" artificial intelligence software project due to a lack of profitability prospects and is now focused exclusively on hematopoietic stem cell expansion.
- Acquisition: Pluristem Ltd. became a wholly-owned subsidiary on June 10, 2003.
- Intellectual Property: The Company secured an exclusive license for stem cell expansion technology from the Weizmann Institute of Science and the Technion-Israel Institute of Technology, including rights to U.S. patent application PCT/US00/02688.
- Management Changes: Dr. Irit Arbel was appointed President, Chief Executive Officer, and Director on May 30, 2003. Harvey M.J. Lawson remains a Director and Treasurer.
Guidance, Outlook, and Risks
Outlook and Strategy: The Company plans to operate through four stages over the next three to four years: Culture Foundation, Co-Culture Development, Characterization & Protein Analysis, and Regulatory Approval. The goal is to file an Investigational New Drug (IND) or Investigational Device Exemption (IDE) application with the FDA to initiate human clinical trials. The Company anticipates establishing stem cell expansion clinics in the United States and Europe following regulatory approval.
Risks and Contingencies:
- Regulatory Approval: The technology is in the development stage. There is no assurance that the FDA or other authorities will approve the PluriX™ Bioreactor system. The process is lengthy, expensive, and uncertain.
- Lack of Profitability: The Company has no operating history in biotechnology and expects no revenues for the next three years. It is dependent on raising additional capital, likely through private placements, which will cause dilution to existing shareholders.
- Intellectual Property: Success depends on maintaining patent rights and avoiding infringement claims. The Company relies on a license from third parties (Weizmann and Technion) which could be terminated.
- Geopolitical Risk: Principal R&D facilities are located in Israel, exposing the Company to risks associated with military and political unrest in the region.
- Competition: The biotechnology sector is highly competitive with established companies possessing significantly greater resources.
Investor Verification Checklist
- Verify the status of the US$500,000 line of credit provided to Pluristem and the Company's current cash position to fund the projected $1.9 million in expenses for the next fiscal year.
- Confirm the validity and scope of the exclusive license agreement with the Weizmann Institute of Science and the Technion-Israel Institute of Technology.
- Monitor the timeline for filing the Investigational New Drug (IND) or Investigational Device Exemption (IDE) application with the FDA.
- Assess the Company's ability to raise additional capital given the "penny stock" status and lack of current revenue.
- Review the pending patent applications (PCT/US00/02688) and the status of the South African patent issued in October 2002.